메뉴 건너뛰기




Volumn 60, Issue 9, 2011, Pages 1271-1277

Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CYCLIC AMP; GLUCAGON LIKE PEPTIDE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; SMOOTH MUSCLE ACTIN;

EID: 80051800781     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2011.01.010     Document Type: Article
Times cited : (94)

References (29)
  • 1
    • 0029882358 scopus 로고    scopus 로고
    • Recent progress in advanced glycation and diabetic vascular disease: Role of advanced glycation end product receptors
    • H. Vlassara, and R. Bucala Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors Diabetes Suppl 3 1996 S65 S66
    • (1996) Diabetes Suppl , vol.3
    • Vlassara, H.1    Bucala, R.2
  • 2
    • 0023950461 scopus 로고    scopus 로고
    • Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
    • M. Brownlee, A. Cerami, and H. Vlassara Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications N Engl J Med 318 1998 1315 1321
    • (1998) N Engl J Med , vol.318 , pp. 1315-1321
    • Brownlee, M.1    Cerami, A.2    Vlassara, H.3
  • 3
    • 21044443182 scopus 로고    scopus 로고
    • Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy
    • DOI 10.2174/1381612054367300
    • S. Yamagishi, and T. Imaizumi Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy Curr Pharm Des 11 2005 2279 2299 (Pubitemid 40872698)
    • (2005) Current Pharmaceutical Design , vol.11 , Issue.18 , pp. 2279-2299
    • Yamagishi, S.-I.1    Imaizumi, T.2
  • 5
    • 35348927441 scopus 로고    scopus 로고
    • Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation and products (sRAGE) in diabetes
    • DOI 10.2174/138945007782151298
    • S. Yamagishi, T. Matsui, and K. Nakamura Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes Curr Drug Targets 8 2007 1138 1143 (Pubitemid 47578142)
    • (2007) Current Drug Targets , vol.8 , Issue.10 , pp. 1138-1143
    • Yamagishi, S.-I.1    Matsui, T.2    Nakamura, K.3
  • 8
    • 77955414324 scopus 로고    scopus 로고
    • Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation
    • Y. Ide, T. Matsui, Y. Ishibashi, M. Takeuchi, and S. Yamagishi Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation Microvasc Res 80 2010 227 232
    • (2010) Microvasc Res , vol.80 , pp. 227-232
    • Ide, Y.1    Matsui, T.2    Ishibashi, Y.3    Takeuchi, M.4    Yamagishi, S.5
  • 9
    • 58149090676 scopus 로고    scopus 로고
    • The role of incretins in glucose homeostasis and diabetes treatment
    • W. Kim, and J.M. Egan The role of incretins in glucose homeostasis and diabetes treatment Pharmacol Rev 60 2008 470 512
    • (2008) Pharmacol Rev , vol.60 , pp. 470-512
    • Kim, W.1    Egan, J.M.2
  • 10
    • 36148996843 scopus 로고    scopus 로고
    • G-protein-coupled receptors and islet function-Implications for treatment of type 2 diabetes
    • DOI 10.1016/j.pharmthera.2007.08.002, PII S0163725807001593
    • M.S. Winzell, and B. Ahrén G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes Pharmacol Rev 116 2007 437 448 (Pubitemid 350116941)
    • (2007) Pharmacology and Therapeutics , vol.116 , Issue.3 , pp. 437-448
    • Winzell, M.S.1    Ahren, B.2
  • 11
    • 38849195749 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 attenuates tumour necrosis factor-"-mediated induction of plasmogen activator inhibitor-1 expression
    • DOI 10.1677/JOE-07-0387
    • H. Liu, Y. Hu, R.W. Simpson, and A.E. Dear Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasmogen activator inhibitor-1 expression J Endocrinol 196 2008 57 65 (Pubitemid 351234571)
    • (2008) Journal of Endocrinology , vol.196 , Issue.1 , pp. 57-65
    • Liu, H.1    Hu, Y.2    Simpson, R.W.3    Dear, A.E.4
  • 12
    • 73949118948 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression
    • Y. Ishibashi, T. Matsui, M. Takeuchi, and S. Yamagishi Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression Biochem Biophys Res Commun 391 2010 1405 1408
    • (2010) Biochem Biophys Res Commun , vol.391 , pp. 1405-1408
    • Ishibashi, Y.1    Matsui, T.2    Takeuchi, M.3    Yamagishi, S.4
  • 13
    • 67650057935 scopus 로고    scopus 로고
    • A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules
    • H. Liu, A.E. Dear, L.B. Knudsen, and R.W. Simpson A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules J Endocrinol 201 2009 59 66
    • (2009) J Endocrinol , vol.201 , pp. 59-66
    • Liu, H.1    Dear, A.E.2    Knudsen, L.B.3    Simpson, R.W.4
  • 14
    • 33750913676 scopus 로고    scopus 로고
    • Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation
    • DOI 10.1007/s00125-006-0437-7
    • T. Yoshida, S. Yamagishi, and K. Nakamura Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation Diabetologia 49 2006 3094 3099 (Pubitemid 44730314)
    • (2006) Diabetologia , vol.49 , Issue.12 , pp. 3094-3099
    • Yoshida, T.1    Yamagishi, S.2    Nakamura, K.3    Matsui, T.4    Imaizumi, T.5    Takeuchi, M.6    Koga, H.7    Ueno, T.8    Sata, M.9
  • 15
    • 0033304603 scopus 로고    scopus 로고
    • The glucagon-like peptides
    • T.J. Kieffer, and J.F. Habener The glucagon-like peptides Endocr Rev 20 1999 876 913 (Pubitemid 30647076)
    • (1999) Endocrine Reviews , vol.20 , Issue.6 , pp. 876-913
    • Kieffer, T.J.1    Habener, J.F.2
  • 16
    • 33947580463 scopus 로고    scopus 로고
    • Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells
    • T. Matsui, S. Yamagishi, K. Nakamura, M. Takeuchi, and H. Inoue Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells J Int Med Res 35 2007 107 112 (Pubitemid 46477534)
    • (2007) Journal of International Medical Research , vol.35 , Issue.1 , pp. 107-112
    • Matsui, T.1    Yamagishi, S.2    Nakamura, K.3    Inoue, H.4    Takeuchi, M.5
  • 17
    • 0031773362 scopus 로고    scopus 로고
    • Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells
    • DOI 10.1007/s001250051089
    • S. Yamagishi, H. Fujimori, H. Yonekura, Y. Yamamoto, and H. Yamamoto Advanced glycation end products inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells Diabetologia 41 1998 1435 1441 (Pubitemid 28551614)
    • (1998) Diabetologia , vol.41 , Issue.12 , pp. 1435-1441
    • Yamagishi, S.1    Fujimori, H.2    Yonekura, H.3    Yamamoto, Y.4    Yamamoto, H.5
  • 18
    • 0036765450 scopus 로고    scopus 로고
    • 2 analogue, protects against advanced glycation end products-induced injury in cultured retinal pericytes
    • S. Yamagishi, S. Amano, Y. Inagaki, T. Okamoto, M. Takeuchi, and Z. Makita Beraprost sodium, a prostaglandin I2 analogue, protects against advanced glycation end products-induced injury in cultured retinal pericytes Mol Med 8 2002 546 550 (Pubitemid 36332366)
    • (2002) Molecular Medicine , vol.8 , Issue.9 , pp. 546-550
    • Yamagishi, S.-I.1    Amano, S.2    Inagaki, Y.3    Okamoto, T.4    Takeuchi, M.5    Makita, Z.6
  • 19
    • 0037036345 scopus 로고    scopus 로고
    • Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells
    • DOI 10.1074/jbc.M202634200
    • S. Yamagishi, Y. Inagaki, and T. Okamoto Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells J Biol Chem 277 2002 20309 20315 (Pubitemid 34967325)
    • (2002) Journal of Biological Chemistry , vol.277 , Issue.23 , pp. 20309-20315
    • Yamagishi, S.-I.1    Inagaki, Y.2    Okamoto, T.3    Amano, S.4    Koga, K.5    Takeuchi, M.6    Makita, Z.7
  • 20
    • 0033865561 scopus 로고    scopus 로고
    • Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy
    • DOI 10.1046/j.1523-1755.2000.00214.x
    • N. Banba, T. Nakamura, and M. Matsumura Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy Kidney Int 58 2000 684 690 (Pubitemid 30620017)
    • (2000) Kidney International , vol.58 , Issue.2 , pp. 684-690
    • Banba, N.1    Nakamura, T.2    Matsumura, M.3    Kuroda, H.4    Hattori, Y.5    Kasai, K.6
  • 22
    • 30944456936 scopus 로고    scopus 로고
    • Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice
    • DOI 10.1038/sj.ki.5000014, PII 5000014
    • F.Y. Chow, D.J. Nikolic-Paterson, and E. Ozols Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice Kidney Int 69 2006 73 80 (Pubitemid 43117741)
    • (2006) Kidney International , vol.69 , Issue.1 , pp. 73-80
    • Chow, F.Y.1    Nikolic-Paterson, D.J.2    Ozols, E.3    Atkins, R.C.4    Rollin, B.J.5    Tesch, G.H.6
  • 23
    • 60549097258 scopus 로고    scopus 로고
    • Targeting incretins in type 2 diabetes: Role of GLP-1 receptor agonists and DPP-4 inhibitors
    • R.E. Pratley, and M. Gilbert Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors Rev Diabet Stud 5 2008 73 94
    • (2008) Rev Diabet Stud , vol.5 , pp. 73-94
    • Pratley, R.E.1    Gilbert, M.2
  • 25
    • 77954798308 scopus 로고    scopus 로고
    • Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects
    • A. Sarashina, S. Sesoko, and M. Nakashima Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects Clin Ther 32 2010 1188 1204
    • (2010) Clin Ther , vol.32 , pp. 1188-1204
    • Sarashina, A.1    Sesoko, S.2    Nakashima, M.3
  • 26
    • 0036676385 scopus 로고    scopus 로고
    • Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects
    • DOI 10.2337/diacare.25.8.1398
    • B. Elbrønd, G. Jakobsen, and S. Larsen Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects Diabetes Care 25 2002 1398 1404 (Pubitemid 41071152)
    • (2002) Diabetes Care , vol.25 , Issue.8 , pp. 1398-1404
    • Elbrond, B.1    Jakobsen, G.2    Larsen, S.3    Agerso, H.4    Jensen, L.B.5    Rolan, P.6    Sturis, J.7    Hatorp, V.8    Zdravkovic, M.9
  • 28
    • 0032810308 scopus 로고    scopus 로고
    • Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients
    • M. Takeuchi, Z. Makita, K. Yanagisawa, K. Kameda, and T. Koike Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients Mol Med 5 1999 393 405 (Pubitemid 29382313)
    • (1999) Molecular Medicine , vol.5 , Issue.6 , pp. 393-405
    • Takeuchi, M.1    Makita, Z.2    Yanagisawa, K.3    Kameda, Y.4    Koike, T.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.